Zomanex Overview

  • Founded
  • 2006
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Zomanex General Information


Operator of a drug formulation development company intended to transform intravenous, injectable, and oral therapeutics into novel orally delivered medicines. The company's products help in the conversion of intravenous or injectable xenobiotics into orally deliverable substances, as well as make it easy for hydrophobic compounds to be absorbed in the small intestine, enabling physicians to permit oral dosing of pharmaceutical compounds that have previously been administered intravenously or by injection.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Primary Office
  • Three Bentall Centre, P.O. Box 49314
  • Suite 2600, 595 Burrard Street
  • Vancouver, British Columbia V7X 1L3
  • Canada
+1 (604) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zomanex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Generating Revenue
To view Zomanex’s complete valuation and funding history, request access »

Zomanex Executive Team (3)

Name Title Board Seat Contact Info
Paul Drohan Chief Executive Officer
Curtis Spilburg Ph.D Chief Scientific Officer
Doris Schnelle Director, Business Development
To view Zomanex’s complete executive team members history, request access »

Zomanex Board Members (1)

Name Representing Role Since
Peter Craddock Shoreline Venture Management Board Member 000 0000
To view Zomanex’s complete board members history, request access »

Zomanex Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shoreline Venture Management Venture Capital Minority 000 0000 000000 0
To view Zomanex’s complete investors history, request access »